Fate Therapeutics (FATE) PT Raised to $33 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $2.08 +1.96%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Wedbush analyst David Nierengarten raised the price target on Fate Therapeutics (NASDAQ: FATE) to $33.00 (from $29.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Marriott International (MAR) PT Lowered to $141 at Jefferies
- United Therapeutics Corp. (UTHR) PT Raised to $720 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
